Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Inluriyo (imlunestrant) is an oral estrogen receptor (ER) antagonist that delivers continuous ER inhibition, including in cancers with ESR1 mutations that commonly drive resistance to earlier hormone therapy. It is indicated for the treatment of adults with:
It is a prescription oncology medicine and must be used under the supervision of a qualified oncologist, typically after ESR1 mutation testing confirms eligibility.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Inluriyo (imlunestrant) tablets may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Inluriyo (imlunestrant tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Inluriyo is not commercially marketed in India.
However, patients in India can legally access Inluriyo through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Inluriyo received US FDA approval on 25 September 2025, ensuring full transparency throughout the process.
Inluriyo can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NPP also facilitates access to other targeted therapies for ER-positive, HER2-negative breast cancer, including Orserdu (elacestrant), Veppanu (vepdegestrant), and Trodelvy (sacituzumab govitecan), for patients whose treating oncologist considers these options relevant to their case.
NamedPatientProgram.com (NPP) can source Inluriyo from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. Inluriyo tablets should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and are handled under temperature-controlled shipping conditions throughout transit. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Inluriyo cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Inluriyo through regulated import pathways, with delivery arranged to the treating hospital based on a valid oncologist's prescription.
A major oncology hub with institutions like Tata Memorial, Mumbai coordinates access to advanced breast cancer therapies like Inluriyo for eligible patients.
As part of the Delhi NCR region, the city has a strong concentration of cancer centers, making it a key location for accessing targeted breast cancer treatments.
With a growing network of multispecialty oncology hospitals, Bangalore supports access to Inluriyo through structured import pathways guided by treating specialists.
Home to several reputed cancer treatment centers, Chennai facilitates access to Inluriyo for patients with ESR1-mutated breast cancer.
A growing hub for oncology care, Hyderabad supports coordinated access to Inluriyo for eligible patients under specialist supervision.
Eastern India's leading cancer centers in Kolkata coordinate Inluriyo access for patients with advanced breast cancer.
With an expanding base of oncology clinics, Pune facilitates timely access to Inluriyo under prescription.
Gujarat's leading cancer hospitals support regulated access to Inluriyo for eligible patients.
Kerala's healthcare network, including major cancer centers in Kochi, coordinates access to advanced oral oncology therapies like Inluriyo.
Serving North India, Chandigarh's oncology centers facilitate access to Inluriyo for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Inluriyo through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Inluriyo under oncologist care.
Odisha's growing oncology sector supports patient access to Inluriyo.
As a referral hub for the North-East, Guwahati facilitates access to Inluriyo for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
